Patent classifications
C12Y401/01002
CRYSTALLIZED OXALATE DECARBOXYLASE AND METHODS OF USE
Pharmaceutical compositions comprising spray-dried oxalate decarboxylase crystals are disclosed. Methods to treat a disorder associated with elevated oxalate concentration using compositions comprising spray-dried oxalate decarboxylase crystals are also disclosed.
METHODS OF TREATING HYPEROXALURIA
Disclosed are methods and compositions which can be used to treat diseases or disorders associated with an elevated amount of oxalate, including, for example, hyperoxaluria, in particular enteric hyperoxaluria.
Recombinant oxalate decarboxylase expressed in filamentous fungi
The present invention relates to a recombinant OxDC expressed in a filamentous fungal host cell, methods for constructing a recombinant filamentous fungal host cell, methods for producing recombinant OxDC and the application thereof. The recombinant filamentous fungal host cell comprises one or more copies of OxDC expression cassette integrated in its genome; the expression cassette comprises a promoter, a signal peptide coding sequence, an OxDC coding sequence and a transcription terminator. The host cell can be constructed by random integration or site-specific integration. In addition, the present invention also optimizes the medium formulation for different recombinant filamentous fungal host cells. In the production of the recombinant OxDC, the final yield and enzyme activity were greatly improved. The invention effectively solves the problem that the production of OxDC in the prior art cannot be industrialized on a large scale.
BACTERIA ENGINEERED TO TREAT DISORDERS IN WHICH OXALATE IS DETRIMENTAL
The present invention provides recombinant bacterial cells comprising at least one heterologous gene encoding at least one oxalate catabolism enzyme. In another aspect, the recombinant bacterial cells further comprise at least one heterologous gene encoding an importer of oxalate. The invention further provides pharmaceutical compositions comprising the recombinant bacteria, and methods for treating disorders in which oxalate is detrimental, such as hyperoxaluria, using the pharmaceutical compositions of the invention.
High efficiency oxalate-degrading enzymes for degradation of insoluble and soluble oxalate
Disclosed herein are oxalate inducing enzymes with pH and thermal stability and methods of using for oxalate related conditions for in food processing.
Purification and isolation of recombinant oxalate degrading enzymes and spray-dried particles containing oxalate degrading enzymes
The present invention comprises methods and compositions for the reduction of oxalate in humans, and methods for the purification and isolation of recombinant oxalate reducing enzyme proteins. The invention provides methods and compositions for the delivery of oxalate-reducing enzymes in particle compositions. The compositions of the present invention are suitable in methods of treatment or prevention of oxalate-related conditions.
Methods and compositions for treating oxalate-related conditions
The subject invention relates in one aspect to an oxalate degrading composition, which includes at least one oxalate degrading enzyme. The composition includes an enriched insoluble component of fungal bio sample, and the composition is effective to degrade oxalate at a pH of 1.9 or higher. The composition is protected from protease degradation such as pepsin, trypsin and chymotrypsin. The composition is capable of withstanding the conditions of the stomach, small intestines, and/or large intestines of a subject.
Crystallized oxalate decarboxylase and methods of use
Oxalate decarboxylase crystals, including stabilized crystals, such as cross-linked crystals of oxalate decarboxylase, are disclosed. Methods to treat a disorder associated with elevated oxalate concentration using oxalate decarboxylase crystals are also disclosed. Additionally disclosed are methods of producing protein crystals.
Crystallized oxalate decarboxylase and methods of use
Pharmaceutical compositions comprising spray-dried oxalate decarboxylase crystals are disclosed. Methods to treat a disorder associated with elevated oxalate concentration using compositions comprising spray-dried oxalate decarboxylase crystals are also disclosed.
BIOREMEDIATION OF XENOBIOTICS IN THE HONEY BEE HIVE
Described herein are engineered cells, enzymes, methods of use, and bee bread incorporating engineered cells and enzymes as described herein. In certain aspects, described herein are a bacterium containing therein one or more stably-expressing expression vectors for exogenous expression of one or more recombinant carboxylesterase enzymes or oxalate decarboxylase enzymes, thereby providing the engineered cell an exogenous pathway for hydrolyzing ester bonds or removing a carboxyl group. Engineered cells and recombinant enzymes as described herein can be incorporated into bee bread to be fed to a member of the Apidae family of bees or of the Apis or Bombus genus. In additional aspects, such bacteria can also be selected and amplified from the milieu of the hive microorganisms and in some cases they can be molecularly bred to enhance their metabolic capabilities without genetic engineering.